

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/011302

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07K16/28 A61K39/395 G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE KROON ET AL.: "Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systemically disseminated human non-Hodgkin's lymphoma B cells in Scid mice" EXPERIMENTAL HEMATOLOGY, vol. 24, 1996, pages 919-926, XP008030315 Paragraph "Materials and methods", "cell lines", the sentence before the last sentence. Paragraph "Results", "effect of anti-CD52 (Campath-1G) mab treatment", second paragraph. ----- -/-	1,6,7, 10-13
Y		14

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"8" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

2 March 2005

06.07.2005

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Vadot, P

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TONE ET AL: "Structure and chromosomal location of mouse and human CD52 genes" BIOCHEMICA AND BIOPHYSICA ACTA, vol. 1446, 1999, pages 334-340, XP002278471 See introduction -----	1-15
A	A. DOMAGALA ET AL.: "CD52 antigen - a review" MED SCI MONIT, vol. 7, no. 2, 2001, pages 325-331, XP001190887 the whole document -----	1-15
A	WORTH LL ET AL.: "Biologic response modifiers in pediatric cancer" PEDIATRIC ONCOLOGY, vol. 15, no. 4, August 2001 (2001-08), pages 723-740, XP008030314 the whole document -----	1-15
A	WO 03/050257 A (UNIV FLORIDA) 19 June 2003 (2003-06-19) pages 2-3 -----	14
Y		14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/011302

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-15 all partially

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-15 (all partially)

Use of a ligand of CDw52 for the preparation of a medicament for the treatment/diagnosis of solid tumours expressing said cellular marker. Methods of screening ligands of Cdw52 and methods for the production thereof.

2. claims: 1-15 (all partially)

Use of a ligand of Claudin7 for the preparation of a medicament for the treatment/diagnosis of solid tumours expressing said cellular marker. Methods of screening ligands of Claudin7 and methods for the production thereof.

3. claims: 1-15 (all partially)

Use of a ligand of Ephrin A1 for the preparation of a medicament for the treatment/diagnosis of solid tumours expressing said cellular marker. Methods of screening ligands of Ephrin A1 and methods for the production thereof.

4. claims: 1-15 (all partially)

Use of a ligand of AMFR for the preparation of a medicament for the treatment/diagnosis of solid tumours expressing said cellular marker. Methods of screening ligands of AMFR and methods for the production thereof.

5. claims: 1-15 (all partially)

Use of a ligand of MME for the preparation of a medicament for the treatment/diagnosis of solid tumours expressing said cellular marker. Methods of screening ligands of MME and methods for the production thereof.

6. claims: 1-15 (all partially)

Use of a ligand of FGFR3 for the preparation of a medicament for the treatment/diagnosis of solid tumours expressing said cellular marker. Methods of screening ligands of FGFR3 and methods for the production thereof.

Information on patent family members

International Application No

PCT/EP2004/011302

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 03050257	A 19-06-2003	AU 2002360525 A1	WO 03050257 A2	23-06-2003 19-06-2003